Correspondence on ‘2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus’ by Aringer et al

The 2019 European League against rheumatism/American College of Rheumatology classification criteria (EULAR/ACR 2019 criteria) for systemic lupus erythematosus (SLE) has introduced a new scoring system to classify SLE. The EULAR/ACR 2019 criteria include positive antinuclear antibody at least once as obligatory entry criterion; followed by additive weighted criteria grouped in seven clinical and three immunological domains and weighted from 2 to 10. Patients fulfilling at least one clinical criterion and accumulating ≥10 points are classified. In validation cohort, a classification threshold score of ≥10 yielded a sensitivity similar to that of the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria (96.1% vs 96.7%) and a specificity similar to that of the ACR 1997 criteria (93.4% vs 93.4%), demonstrating both excellent sensitivity and specificity. However, we have two concerns about its additive criteria and methodology.

First, some gastrointestinal injuries related to SLE, especially lupus enteritis, may be underestimated. Gastrointestinal symptoms are reported to occur in more than 50% of patients with SLE at some point in the course of their disease; however, these symptoms are usually mild. Although lupus enteritis manifestations are not specific (eg, abdominal pain, nausea, vomiting, anorexia and diarrhoea) and have wide range from mild to life-threatening (perforation and fistulisation), it has relatively specific features (‘double-halo’ and ‘comb sign’) on contrast-enhanced CT. The ‘double-halo’ (namely ‘target sign’) is a marker of abnormal bowel wall submucosal thickening, whereas the ‘comb sign’ correlates with mesenteric vessel prominence. However, the described abnormalities can also be seen in patients with pancreatitis, mechanical bowel obstruction, peritonitis or inflammatory bowel disease. Lupus enteritis mainly affects the small intestine; in rare circumstances, the colon and rectum can also be involved. Because of lack of radiology and endoscopy studies on the newly onset SLE, the actual incidence rate of lupus enteritis remains unknown. Recently, we encountered a case of severe lupus enteritis with multiple rectal ulcers and fistulisation formation (figure 1).

Some days before admission, he had cough and low grade fever and this can be explained by mild community-acquired pneumonia and right-side pleural effusion confirmed by his chest CT. After admission, a transthoracic echocardiogram showed a slight pericardial effusion. Pleural or pericardial effusion can be explained by his hypoproteinemia, largely attributable to the protein-losing enteropathy caused by enteritis and rectal ulcers. Although the diagnosis of SLE was subsequently made according to his proteinuria (1.09 g/24 hours), hypocomplementemia (C3: 0.2 g/L, C4: 0.08 g/L) and SLE-specific antibody (anti-dsDNA antibody; >800 IU/mL), in terms of clinical domains in EULAR/ACR 2019 criteria, we felt lupus enteritis ‘triumphing over’ the seven orthodox clinical domains. Unfortunately, lupus enteritis has not yet been considered in ACR 1997 criteria, SLICC 2012 criteria or EULAR/ACR 2019. It is not even a candidate criteria in patients with early SLE.

Second, rheumatologists should be informed of exact probability of illness in patients with underlying SLE who are below the threshold (ie, total score <10) so as to provide better decision-making, evaluation and follow-up. It is preferable to use logistic regression and nomogram to predict the probability. In addition, when patients have signs or symptoms suggestive of but not diagnostic of SLE, their physician must decide whether to (1) treat empirically, (2) not treat or (3) perform further diagnostic testing before deciding between options 1 and 2. Under this circumstance, decision-making based on the threshold of 10 generated by the receiver operating characteristics analysis seems risky, especially when clinical and immunologic parameters are ambiguous. Rheumatologists should also be informed of the net benefit from the patients when diagnosis is made and treatment is given at a threshold of 10. This net benefit comparison should be suggested to carry out among ACR 1997 criteria, SLICC 2012 criteria, and EULAR/ACR 2019 criteria.

Ran Cui,1 Qian Wang,1 Hua Zhang,1 Shan Wu,2 Xin-Jian Wan,2 Sheng-Ming Dai1

1Department of Rheumatology and Immunology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
2Department of Endoscopy, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

Correspondence to Professor Sheng-Ming Dai, Department of Rheumatology and Immunology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China; shengmingdai@163.com

Contributors Concept and writing: RC and SMD; revising: SMD and XJW; acquiring data: RC, QW, HZ, SW; analysis and interpretation of data: RC and SMD.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.
Correspondence

Patient and public involvement. Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication. Obtained.

Provenance and peer review. Not commissioned; internally peer reviewed.

Open access. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.


Received 9 July 2020
Accepted 11 July 2020

ORCID ID
Ran Cui http://orcid.org/0000-0003-4923-5882

REFERENCES